Ion-Ion Correlation Effect on the Neutrino-Nucleus Scattering in Supernova Cores

We calculate the ion-ion correlation effect on the neutrino-nucleus scattering in supernova cores, which is an important opacity source for the neutrinos and plays a vital role in the supernova explosion. In order to calculate the ion-ion correlation effect we use the results of the improved hypernetted-chain method calculations of the classical one-component plasma. As in the preceding studies on this effect, we find a dramatic decrease of the effective neutrino-nucleus scattering cross section for relatively low energy neutrinos with E < 20MeV. As a matter of fact, our calculation shows a much more dramatic reduction of the effective neutrino-nucleus scattering cross section for the low energy neutrinos with E < 10MeV than the results of Horowitz. Therefore, the ion-ion correlation effect will be more important than has hitherto been recognized. We present an accurate analytic fitting formula that summarizes our numerical results. This fitting formula will facilitate the application of the present results to the supernova explosion simulations.Comment: 10 pages, 2 figures, 1 subroutine, published in ApJ 611, 1041-1044 (2004

Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti–Programmed Cell Death-1 Therapy in NSCLC

Introduction: Programmed cell death-1 (PD-1) inhibitors effectively treat NSCLC and prolong survival. Robust biomarkers for predicting clinical benefits of good response and long survival with anti-PD-1 therapy have yet to be identified; therefore, predictive biomarkers are needed to select patients with benefits. Methods: We conducted a prospective study to explore whether serum antibody against NY-ESO-1 and/or XAGE1 cancer-testis antigens predicted primarily good clinical response and secondarily long survival with anti-PD-1 therapy for NSCLC. The serum antibody was detected by enzyme-linked immunosorbent assay, and tumor immune microenvironment and mutation burden were analyzed by immunohistochemistry and next-generation sequencing. Results: In the discovery cohort (n = 13), six antibody-positive NSCLC cases responded to anti-PD-1 therapy (two complete and four partial responses), whereas seven antibody-negative NSCLC cases did not. Antibody positivity was associated with good response and survival, regardless of tumor programmed death ligand 1 (PD-L1) expression, mutation burden, and CD8+ T-cell infiltration. In the validation cohort (n = 75), 17 antibody-positive NSCLC cases responded well to anti-PD-1 therapy as compared with 58 negative NSCLC cases (objective response rate 65% versus 19%, p = 0.0006) and showed significantly prolonged progression-free survival and overall survival. Antibody titers highly correlated with tumor reduction rates. In the multivariate analysis, response biomarkers were tumor programmed death ligand 1 expression and antibody positivity, and only antibody positivity was a significantly better predictive biomarker of progression-free survival (hazard ratio = 0.4, p = 0.01) and overall survival (hazard ratio = 0.2, p = 0.004). Conclusions: Our results suggest that NY-ESO-1 and/or XAGE1 serum antibodies are useful biomarkers for predicting clinical benefits in anti-PD-1 therapy for NSCLC and probably for other cancers